Results of additional testing have been recently announced by Antibe Therapeutics pertaining to
the progress of the developmental procedures being conducted by the company for their ATB-346
drug.
These recent validation data show further proof that ATB-346 can be effective even if administered
at a lower dosage. The frequency of taking it has also been proven to be effective at a once-a-day
rate.
ATB-346 is a Non-Steroidal Anti-Inflammatory Drug (NSAID); a Naproxen derivative that releases
hydrogen-sulfide. Its primary mechanism of action includes Cyclo oxygenase (COX) as inhibitor. Testing for the product has been made using dosages that range from 25 milligrams up to 1,000
milligrams. During the testing, inhibition was maintained for 24 hours, they also found that it can provide substantial inhibition for doses as low as 75 milligrams.
Development for ATB-346 has been started in the earlier part of the decade presenting potential
advantages for relief of inflammatory disorders without the common side effects. Unlike other
similar NSAIDs like Ibuprofen and Aspirin, ATB-346 is seen to be a potent drug with similar efficacy yet reduced the negative impacts on the gastrointestinal tract like bleedings and ulcers that are commonly caused by its counterparts. It was found out in various related studies on hydrogen-sulfide that the substance is a prospective gastrointestinal protective agent. Due to the hydrogen-sulfide releasing capacity of the drug, ATB-346 can protect the stomach from further ulcers and bleeding and even hasten the healing of pre-existing injuries.
As the development and testing of the product continues, Antibe Therapeutics is set to release
additional validation results as they advance.